To include your compound in the COVID-19 Resource Center, submit it here.

FDA accepts Bayer’s BLA for hemophilia A candidate

Bayer AG (Xetra:BAYN) said FDA accepted for review a BLA for BAY94-9027 to treat hemophilia

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE